Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Everus Construction Group, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the lawsuit is defined as between October 31, 2024, and February 11, 2025, inclusive [1]. - Investors who held MDU Resources common stock as of October 21, 2024, and acquired Everus Construction common stock during the spinoff may be eligible for compensation [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 3, 2025 [3]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [4]. - Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered substantial amounts for investors [4]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, defendants made false or misleading statements regarding Everus Construction's business operations [5]. - Specific claims include that the backlog conversion cycle had elongated due to larger projects, leading to delayed revenue recognition [5]. - The lawsuit asserts that the positive statements made by defendants were materially misleading and lacked a reasonable basis [5].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Organon & Co. securities for the period between October 31, 2024, and April 30, 2025, due to misleading statements regarding the company's capital allocation and dividend strategy [1][5]. Group 1: Lawsuit Details - The lawsuit alleges that Organon provided positive statements while concealing material adverse facts about its priorities, particularly regarding capital allocation and a significant reduction in quarterly dividends [5]. - Following the acquisition of Dermavant, Organon prioritized debt reduction, leading to a 70% decrease in the regular quarterly dividend, which was not disclosed to investors [5]. Group 2: Participation Information - Investors who purchased Organon securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A class action lawsuit has been filed against Krispy Kreme, Inc. for misleading statements regarding its partnership with McDonald's and the subsequent decline in product demand, with a lead plaintiff deadline set for July 15, 2025 [1][4]. Group 1: Lawsuit Details - The lawsuit alleges that Krispy Kreme made false and misleading statements about the demand for its products at McDonald's locations, which materially declined after the initial marketing launch [4]. - It is claimed that the declining demand at McDonald's was a significant factor in the decrease of average sales per door per week [4]. - The partnership with McDonald's is stated to have been unprofitable, posing risks to its continuation and leading to a pause in expansion into new locations [4]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [3]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [3]. Group 3: Participation Information - Investors who purchased Krispy Kreme securities during the class period may be entitled to compensation without upfront fees through a contingency fee arrangement [1]. - To join the class action, investors can submit a form or contact the Rosen Law Firm for more information [2][5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Open Lending Corporation securities during the specified class period of the upcoming lead plaintiff deadline on June 30, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Open Lending securities between February 24, 2022, and March 31, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by June 30, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Open Lending - The lawsuit alleges that Open Lending's defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and operations [5]. - Specific allegations include misrepresentation of Open Lending's risk-based pricing models, misleading statements regarding profit share revenue, and failure to disclose the devaluation of vintage loans from 2021 and 2022 [5]. - The lawsuit claims that these misleading statements resulted in investor damages when the true details became public [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of West Pharmaceutical Services, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 7, 2025 [1]. Group 1: Class Action Details - Investors who bought West common stock between February 16, 2023, and February 12, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lead plaintiff must file a motion with the Court by July 7, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time and has been ranked highly for its performance in this area [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]. Group 3: Case Allegations - The lawsuit alleges that West Pharmaceutical Services made false and misleading statements regarding its business operations, particularly concerning its High-Value Products portfolio and the SmartDose device [5]. - It is claimed that West was experiencing significant destocking and operational inefficiencies that were not disclosed, leading to misleading positive statements about the company's prospects [5]. - The lawsuit asserts that these undisclosed issues resulted in damages to investors when the true situation became known [5].

Core Viewpoint - Rosen Law Firm is reminding investors of Zenas BioPharma, Inc. about a class action lawsuit related to the company's IPO, with a lead plaintiff deadline set for June 16, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased Zenas BioPharma securities may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lawsuit alleges that the Registration Statement contained false or misleading statements regarding the company's financial sustainability and operations funding [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company at the time [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Digimarc Corporation during the specified class period of the upcoming lead plaintiff deadline on July 8, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Digimarc securities between May 3, 2024, and February 26, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by July 8, 2025 [2]. - The lawsuit alleges that Digimarc made false and misleading statements regarding its business operations and revenue, which led to investor damages when the truth was revealed [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements since 2013 [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Elevance Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class action lawsuit pertains to allegations that Elevance Health made false or misleading statements regarding the impact of Medicaid redetermination on its financial guidance and cost trends [4]. - Investors who purchased Elevance common stock between April 18, 2024, and October 16, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][4]. - The deadline to move the Court to serve as lead plaintiff is July 11, 2025, and a lead plaintiff acts on behalf of other class members [2]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [3]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at the time and ranking highly in securities class action settlements since 2013 [3]. Group 3: Case Specifics - The lawsuit claims that Elevance Health misrepresented the adequacy of its premium rates and the monitoring of cost trends related to Medicaid, leading to significant investor damages when the true situation was revealed [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Everus Construction Group, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who acquired Everus Construction common stock between October 31, 2024, and February 11, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 3, 2025 [3]. Group 2: Case Background - The lawsuit alleges that during the Class Period, defendants made false or misleading statements regarding Everus Construction's backlog conversion cycle, which had become elongated due to larger, more complex projects [5]. - It is claimed that this elongation led to delays in revenue recognition, and the positive statements made by defendants about the company's business and prospects were materially misleading [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Digimarc Corporation during the specified Class Period of the upcoming lead plaintiff deadline on July 8, 2025, and the potential for compensation without out-of-pocket costs [1][2]. Group 1: Class Action Details - A class action lawsuit has been filed against Digimarc Corporation, and investors can join the action by contacting Rosen Law Firm [2][5]. - The lawsuit alleges that Digimarc made false and misleading statements regarding its business operations, specifically about a large commercial partner not renewing a significant contract, which adversely affected subscription and annual recurring revenue [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has consistently ranked in the top 4 for securities class action settlements since 2013 [3].